Posted by Michael Wonder on 17 Jan 2022
Keytruda reimbursement boosts MSD’s R&D of follow-up drug
17 January 2022 - The government’s recognition of MSD’s Keytruda (pembrolizumab) for reimbursement as the first-line therapy for lung cancer has accelerated the company’s development of another oncology pipeline built from the backbone of Keytruda.
The Health Insurance Review and Assessment Service (HIRA) held a meeting of the Drug Reimbursement Evaluation Committee on Thursday and recognised Keytruda’s eligibility for reimbursement in the first-line therapy of non-small-cell lung cancer for four years after the drug arrived in Korea.
If drug price negotiations go smoothly, Korean lung cancer patients are expected to have insurance benefits in Keytruda treatment.
